Subscribe
shutterstock-113955145-web
sparkstudio / Shutterstock.com
2 July 2014Americas

Genentech adds to breast cancer pipeline with Seragon buyout

Genentech has entered into an agreement to buy Seragon, a San Diego-based biotech company that specialises in developing treatments that target hormone-driven cancers, for up to $1.725 billion.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Puma and CANBridge cancel licensing deal for $20m
2 March 2021   Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Puma and CANBridge cancel licensing deal for $20m
2 March 2021   Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.

More on this story

Big Pharma
Puma and CANBridge cancel licensing deal for $20m
2 March 2021   Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages